Arranta Bio, our enterprise sponsor for Microbiome and Scotland (birthplace of Arranta Bio’s founder and CEO), is a world-class contract development and manufacturing organization (CDMO). Arranta Bio was specifically established to serve companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta means “bold and daring” in Gaelic – a fitting name for a pioneering company!
Lead by an experienced management team and technical experts with a proven track record, Arranta Bio offers the expertise and resources necessary to develop and manufacture promising new microbiome-based therapies that best meet the needs of patients.
How is Arranta Bio contributing to the future of healthcare?
With the COVID-19 pandemic, CDMOs are playing an increasingly important role in providing knowledge, expertise and capacity in breakthrough areas of healthcare. The reliance of CDMO partners is especially prevalent for novel technologies, including Live Biotherapeutic Products (LBPs) that target the microbiome.
Because LBPs are like no other biologic, deep experience in dealing with their nuances is essential to success. With more than 10 years of process development know-how and expertise, Arranta Bio supports healthcare pioneers develop clinical therapies that target gut health and microbiome-related diseases with their ALIVE Biotherapeutic ProductsTM (aLBP) program.
To best serve the evolving market needs, Arranta Bio is making bold moves to increase capacity. The company has recently committed a $100M investment in their facilities to build end-to-end microbiome capacity and support clients from early-stage process development through cGMP clinical supply to commercialization.
With Arranta Bio’s experienced leadership team and accumulated knowledge, the company supports the future of healthcare by providing development and manufacturing services that help bring breakthrough therapies to market and transform the lives of patients around the world.